Mallinckrodt respiratory patents invalidated by court

06-09-2017

Industrial gases company Praxair has been cleared of patent infringement in a district court ruling after Mallinckrodt accused the company of infringing its respiratory treatment Inomax (nitric oxide).


Praxair, Mallinckrodt, patent infringement, patent, US District Court for the District of Delaware, Food and Drug Administration, Abbreviated New Drug Appl

LSIPR